Differences in the predictive value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in advanced ischemic and non-ischemic heart failure

Atherosclerosis

Volumn 213, Issue 2, 2010, Pages 545-548

  Richter, Bernhard ^a   Rychli, Kathrin ^a   Hohensinner, Philipp J ^a   Berger, Rudolf ^a   Mörtl, Deddo ^a   Neuhold, Stephanie ^a   Zorn, Gerlinde ^a   Huber, Kurt ^b   Maurer, Gerald ^a   Wojta, Johann ^a   Pacher, Richard ^a   Hülsmann, Martin ^a   Niessner, Alexander ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b WILHELMINEN HOSPITAL   (Austria)

Author keywords

Apoptosis; Cardiomyocyte proliferation; Cardiomyopathy; Heart failure; Prognosis; Soluble tumor necrosis factor like weak inducer of apoptosis; TWEAK

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CELL PROLIFERATION; CLINICAL ASSESSMENT; COMORBIDITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CELL; HUMAN; ISCHEMIC HEART FAILURE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON ISCHEMIC HEART FAILURE; PREDICTION AND FORECASTING; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL;

AGED; AGED, 80 AND OVER; AUSTRIA; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR NECROSIS FACTORS;

EID: 78649736865     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.08.061     Document Type: Article

References (15)

1. Burkly L.C., Michaelson J.S., Hahm K., Jakubowski A., Zheng T.S. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine 2007, 40:1-16.
2. Kralisch S., Ziegelmeier M., Bachmann A., et al. Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis 2008, 199:440-444.
3. Novoyatleva T., Diehl F., van Amerongen M.J., et al. TWEAK is a positive regulator of cardiomyocyte proliferation. Cardiovasc Res 2010, 85:681-690.
4. Jain M., Jakubowski A., Cui L., et al. A novel role for tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in the development of cardiac dysfunction and failure. Circulation 2009, 119:2058-2068.
5. Chorianopoulos E., Jarr K., Steen H., Giannitsis E., Frey N., Katus H.A. Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome. Atherosclerosis 2010.
6. Chorianopoulos E., Rosenberg M., Zugck C., Wolf J., Katus H.A., Frey N. Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure. Eur J Heart Fail 2009, 11:1050-1056.
7. Niessner A., Hohensinner P.J., Rychli K., et al. Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J 2009, 30:789-796.
8. Maisel A., Mueller C., Nowak R., et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010, 55:2062-2076.
9. Winkles J.A. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008, 7:411-425.
10. Lynch C.N, Wang Y.C., Lund J.K., Chen Y.W., Leal J.A., Wiley S.R. TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem 1999, 274:8455-8459.
11. Maecker H., Varfolomeev E., Kischkel F., et al. TWEAK attenuates the transition from innate to adaptive immunity. Cell 2005, 123:931-944.
12. Moreno J.A., Munoz-Garcia B., Martin-Ventura J.L., et al. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis 2009, 207:103-110.
13. King V.L. Atherosclerosis: should we stop TWEAKing it?. Arterioscler Thromb Vasc Biol 2009, 29:1982-1983.
14. Ortiz A., Sanz A.B., Munoz Garcia B., et al. Considering TWEAK as a target for therapy in renal and vascular injury. Cytokine Growth Factor Rev 2009, 20:251-258.
15. Secchiero P., Corallini F., Beltrami A.P., et al. An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis 2010, 210:274-277.